BioMed Valley Discoveries, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2001-03-30
- Employees
- 1
- Market Cap
- -
- Website
- http://biomed-valley.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
- Conditions
- Tumor, SolidGastrointestinal Cancer
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 47
- Registration Number
- NCT05221320
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
- Conditions
- Advanced Solid TumorBRAF Gene MutationBRAF Gene AlterationMEK MutationMEK AlterationMAP2K1 Gene MutationMAP2K1 Gene AlterationMAP2K2 Gene MutationMAP2K2 Gene Alteration
- Interventions
- Drug: Physician's Choice
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 104
- Registration Number
- NCT04488003
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Christiana Care Health Services / Helen F. Graham Cancer Center, Newark, Delaware, United States
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
- Conditions
- Healthy
- Interventions
- Drug: [14C]-BVD-523
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT02994732
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 53
- Registration Number
- NCT02296242
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
- Conditions
- Solid Tumor Malignancies
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01924689
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Prev
- 1
- 2
- Next